Definium Therapeutics/$DFTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Definium Therapeutics
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
- Ticker
- $DFTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- New York, United States
- Website
- definiumtx.com
DFTX Metrics
BasicAdvanced
$5.1B
-
-$3.48
2.24
-
Price and volume
Market cap
$5.1B
Beta
2.24
52-week high
$49.70
52-week low
$10.46
Average daily volume
2.1M
Financial strength
Current ratio
6.947
Quick ratio
6.895
Long term debt to equity
0.04
Total debt to equity
0.04
Interest coverage (TTM)
-45.33%
Profitability
Management effectiveness
Return on assets (TTM)
-20.64%
Return on equity (TTM)
-64.09%
Valuation
Price to book
5.55
Price to tangible book (TTM)
5.68
Price to free cash flow (TTM)
-22.962
Free cash flow yield (TTM)
-4.35%
Free cash flow per share (TTM)
-1.653
Growth
Earnings per share change (TTM)
143.13%
3-year earnings per share growth (CAGR)
18.37%
What the Analysts think about DFTX
Analyst ratings (Buy, Hold, Sell) for Definium Therapeutics stock.
Analyst projections of the future price of Definium Therapeutics stock.
Bulls say / Bears say
DT120 has cleared two Phase 3 trials in GAD: it beat placebo by 5.4 points in Voyage and 5.1 points in Panorama on the HAM-A at week 12, with both results highly statistically significant. Replication across separate studies makes the anxiety result more convincing. (Definium Therapeutics, Definium Therapeutics)
In MDD, Emerge showed an 8.1-point placebo-adjusted improvement on the MADRS at week six, with benefit still evident at week 12. The FDA’s Breakthrough Therapy designation for MDD adds regulatory momentum in a second major indication. (Definium Therapeutics, Definium Therapeutics)
Definium reported about $1.1 billion in cash, cash equivalents and investments at the end of June and expects it to fund operations into 2030. That gives the company substantial room to advance its late-stage trials and prepare for a potential launch without an immediate need for more capital. (Definium Therapeutics)
The psychedelic effects may compromise blinding: in Panorama, 95% of high-dose participants and 91% of low-dose participants correctly guessed their assignment. That could make symptom ratings more vulnerable to expectancy effects, even if other trial features support a genuine treatment effect. (Mugglehead, Definium Therapeutics)
Treatment may be difficult to scale in ordinary clinics: in Panorama, treatment-emergent adverse events affected 94.8% of the 100 µg group versus 62.9% on placebo, including illusions in 68% of treated participants. Participants took an average of 6.2 hours to meet end-of-session clearance criteria, which may constrain clinic throughput and patient acceptance. (Definium Therapeutics, earningscalls.dev)
The approval route and timing remain uncertain: Definium says it will discuss the GAD and MDD regulatory strategy with the FDA at a pre-NDA meeting in the fourth quarter, and it is targeting an NDA filing in the first half of 2027. The agency’s feedback could affect the filing plan and how quickly DT120 reaches the market. (Definium Therapeutics, Definium Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2026.
DFTX Financial Performance
Revenues and expenses
DFTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
DFTX News
AllArticlesVideos
Funds containing DFTX
Fund name | Fund size | $DFTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.33% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.33% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.16% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.16% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.